Document Detail

Tumour resistance to cisplatin: a modelling approach.
MedLine Citation:
PMID:  15715425     Owner:  NLM     Status:  MEDLINE    
Although chemotherapy has revolutionized the treatment of haematological tumours, in many common solid tumours the success has been limited. Some of the reasons for the limitations are: the timing of drug delivery, resistance to the drug, repopulation between cycles of chemotherapy and the lack of complete understanding of the pharmacokinetics and pharmacodynamics of a specific agent. Cisplatin is among the most effective cytotoxic agents used in head and neck cancer treatments. When modelling cisplatin as a single agent, the properties of cisplatin only have to be taken into account, reducing the number of assumptions that are considered in the generalized chemotherapy models. The aim of the present paper is to model the biological effect of cisplatin and to simulate the consequence of cisplatin resistance on tumour control. The 'treated' tumour is a squamous cell carcinoma of the head and neck, previously grown by computer-based Monte Carlo techniques. The model maintained the biological constitution of a tumour through the generation of stem cells, proliferating cells and non-proliferating cells. Cell kinetic parameters (mean cell cycle time, cell loss factor, thymidine labelling index) were also consistent with the literature. A sensitivity study on the contribution of various mechanisms leading to drug resistance is undertaken. To quantify the extent of drug resistance, the cisplatin resistance factor (CRF) is defined as the ratio between the number of surviving cells of the resistant population and the number of surviving cells of the sensitive population, determined after the same treatment time. It is shown that there is a supra-linear dependence of CRF on the percentage of cisplatin-DNA adducts formed, and a sigmoid-like dependence between CRF and the percentage of cells killed in resistant tumours. Drug resistance is shown to be a cumulative process which eventually can overcome tumour regression leading to treatment failure.
L Marcu; E Bezak; I Olver; T van Doorn
Related Documents :
3710695 - Membrane-associated proteins of adriamycin sensitive and resistant murine leukemic p388...
17067265 - The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a t-lym...
15488635 - Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(i...
2139015 - Hormone and cytotoxic drug responsiveness of cultured human breast cancer cells resista...
303575 - Ultrastructural autoradiographic study of blast cells in the mouse thymus. interest for...
8955125 - The nuclear localization sequences of the brca1 protein interact with the importin-alph...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Physics in medicine and biology     Volume:  50     ISSN:  0031-9155     ISO Abbreviation:  Phys Med Biol     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-02-17     Completed Date:  2005-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401220     Medline TA:  Phys Med Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  93-102     Citation Subset:  IM    
School of Chemistry and Physics, University of Adelaide, North Terrace, SA 5000, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Cell Proliferation
Cell Survival
Cisplatin / chemistry*,  pharmacology*
DNA Adducts / chemistry*
Drug Resistance*
Drug Resistance, Neoplasm*
Models, Statistical
Monte Carlo Method
Neoplasms / drug therapy*,  pathology
Normal Distribution
Stem Cells / cytology
Time Factors
Reg. No./Substance:
0/Antineoplastic Agents; 0/DNA Adducts; 0/cisplatin-DNA adduct; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human epithelial cells increase their rigidity with ageing in vitro: direct measurements.
Next Document:  Quantitative analysis of patient-specific dosimetric IMRT verification.